ArticleCureus2026
Metabolic-Hormonal Interplay and the Case for a Reproductive-Metabolic Framework in the Glucagon-Like Peptide-1 (GLP-1) Era.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS), proposed by some investigators to be more accurately termed polycystic-morphology ovary syndrome (PMOS), reflecting its heterogeneous and not universally cystic pathophysiology, remains the most prevalent endocrine disorder among reproductive-age women worldwide. Despite this, its clinical management continues to be fragmented along specialty lines, with gynecologists addressing menstrual irregularity and contraception, endocrinologists managing insulin resistance and metabolic risk, and dermatologists treating hyperandrogenic manifestations. This editorial proposes the Reproductive-Metabolic Axis (RMA) as a unifying conceptual framework for understanding PCOS/PMOS beyond its phenotypic surface. We argue that contraceptive decision-making in women with PCOS/PMOS cannot be separated from metabolic status, insulin resistance, androgen excess, and cardiovascular risk profiling. In the glucagon-like peptide-1 (GLP-1) receptor agonist era, which has transformed the management of obesity and insulin resistance, new clinical questions arise regarding the interaction between incretin-based therapies, hormonal contraception, and ovarian function restoration. The present editorial does not propose a validated therapeutic protocol, but rather a hypothesis-generating framework that invites further clinical investigation into whether integrated reproductive-metabolic management improves outcomes for women with PCOS/PMOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.